, Axsome's therapy targets several neurotransmitters including glutamate and had succeeded in a late-stage trial in 2019. The long-awaited approval for the therapy comes after the agency found deficiencies in the company's application last year and extended its review of the drug.The World Health Organization says the global prevalence of anxiety and depression increased by 25% in the first year of the COVID-19 pandemic.
Loneliness, fear of infection, suffering and death for oneself and loved ones, grief following bereavement, and financial worries were all cited as factors leading to anxiety and depression. WHO also said depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Approximately 280 million people in the world have depression.Symptoms of depression include depressed mood or a loss of pleasure or interest in activities, for most of the day, nearly every day, for at least two weeks, according to WHO.
If you or a loved one is feeling distressed, call the National Suicide Prevention Lifeline. The crisis center provides free and confidential emotional support 24 hours a day, 7 days a week to civilians and veterans. Call the National Suicide Prevention Lifeline at
Source: News Formal (newsformal.com)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: FOX10Phoenix - 🏆 83. / 68 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »
Source: Slate - 🏆 716. / 51 Read more »
Source: MSTODAYnews - 🏆 275. / 63 Read more »
Source: NBCNews - 🏆 10. / 86 Read more »
Source: BuzzFeed - 🏆 730. / 51 Read more »